Previous close | 276.75 |
Open | 317.41 |
Bid | 290.50 x N/A |
Ask | 0.00 x N/A |
Day's range | 310.81 - 321.96 |
52-week range | 211.96 - 329.12 |
Volume | |
Avg. volume | 35,247 |
Market cap | 167.564B |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | 20.60 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 8.52 (3.04%) |
Ex-dividend date | 17 Aug 2023 |
1y target est | N/A |
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.
Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.